Research programme: anti-infective antibody therapeutics - Regeneron/BARDA

Next Previous
Drug Profile

Research programme: anti-infective antibody therapeutics - Regeneron/BARDA

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biomedical Advanced Research and Development Authority; Regeneron Pharmaceuticals
  • Class Anti-infectives; Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Infections; Influenza virus infections

Most Recent Events

  • 02 Oct 2017 Regeneron Pharmaceuticals and BARDA agree to co-develop antibody therapeutics in USA for Influenza virus infections and other infectious diseases
  • 02 Oct 2017 Early research in Infections in USA (Parenteral)
  • 02 Oct 2017 Early research in Influenza virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top